News
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is pleased to announce the expansion of its leadership team with the ...
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best small cap stocks with biggest upside potential. On August 4, Dyne ...
Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...
Teen whose story touched Post readers gets up-close look at planes and hangars, joining his friends for ‘special’ visit he ...
Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory ...
19hon MSN
Q&A: How organoids could make gene therapy trials safer by identifying hidden risks early on
Ryuji Morizane, MD, Ph.D., of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding ...
Ashfields care home in Rackheath donates £386 to Leon D’Souza for vital home improvements as he battles Duchenne Muscular Dystrophy.
DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular ...
News-Medical.Net on MSN15h
Improving gene therapy safety with human kidney organoids
Ryuji Morizane, MD, PhD, of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding author ...
Keros Therapeutics (KROS)’ treatment of Duchenne muscular dystrophy was granted FDA orphan designation, according to a post to the agency’s site.
Learn more about whether ADMA Biologics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...
Among a clutch of trailblazers at the forefront of the game in the north during the late Noughties, Marc helped break down the barriers to greater facilities and funding – not just through the spirit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback